Precision engineering is one of AIM's quieter strengths, spanning automotive testing, nuclear and energy systems, and photonics. As September 2026 results arrive, AB Dynamics, Avingtrans and Gooch & Housego show three profitable, order-book-driven businesses navigating end-market shifts — from a China-testing setback to booming defence Demand — and demonstrate how quality engineering companies convert order books into Revenue and cash.
FTSE AIM All-Share Engineering Outlook for September 2026
Engineering companies sit at the intersection of several powerful trends. Defence and aerospace spending has risen sharply as governments respond to a more uncertain geopolitical environment; the energy transition and the revival of nuclear power are driving demand for specialist components and systems; the automotive industry's shift towards electrification and autonomy is reshaping vehicle testing; and the semiconductor and photonics markets underpin much of modern technology. AIM's engineering companies are exposed, in different ways, to these structural drivers.
Unlike many junior-market sectors, the engineering names featured here are established, profitable and cash-generative, with order books that provide revenue visibility. That order-book dynamic is central to how they are assessed: a growing, high-quality order book signals future revenue and supports confidence, while a slowdown in order intake or delays in conversion can weigh on sentiment. Margins, and the mix between higher- and lower-margin work, are equally important to their profitability.
External factors shape the group. Currency movements affect companies with significant overseas revenue; capital-investment cycles influence demand for their products; and, for those exposed to specific end-markets such as China or particular industries, sector-specific disruptions can create near-term headwinds even where the long-term drivers remain intact. The three companies here — an automotive-testing specialist, a diversified nuclear-and-energy engineer, and a photonics group riding defence demand — capture the breadth of the FTSE AIM All-Share engineering theme.
AB Dynamics plc (LSE:ABDP)
AB Dynamics is a specialist supplier of testing, simulation and measurement systems to the automotive industry, used in vehicle development, safety testing and the validation of advanced driver-assistance and autonomous-driving systems. Its products — from driving robots and track-testing equipment to simulators and, increasingly, testing services — are used by vehicle manufacturers and regulators worldwide. It is a profitable, cash-generative Business with strong margins, exposed to the automotive industry's long-term shift towards automation and electrification, though not immune to near-term disruption in specific markets.
The company's strategy combines organic growth in its core testing products with expansion into testing services and simulation, and selective acquisitions, aiming for double-digit organic growth and margins above 20% over the medium term.
Latest results and the China setback
For the first half of the 2026 financial year, the six months to 28 February 2026, AB Dynamics reported revenue of £48.8 million, down 16% year on year, with adjusted operating profit also down 16% to £9.1 million and the adjusted operating Margin steady at 18.6%; gross margin actually improved by 350 basis points to 63.7%. The company ended the period with net cash of £39.3 million, up 44%, and an order book of £47 million, and it raised the Interim Dividend 10% to 3.08p per share, reflecting confidence despite the softer half.
The principal drag was in China, where its VadoTech testing-services business experienced significantly weaker volumes than anticipated under a new European original-equipment-manufacturer contract, leading to £16.8 million of exceptional items, primarily a non-cash £12.3 million impairment. Management characterised this as a short-term timing difference rather than a fundamental change in the structural growth drivers, and reaffirmed medium-term ambitions of 10% annual organic growth and margins above 20%. For the full year, absent extended geopolitical disruption, the board expected adjusted operating profit in line with analyst consensus, with revenue weighted 55–60% towards the second half.
The detail beneath the headline decline is reassuring on quality even as it flags near-term risk. A gross margin that improved by 350 basis points and a maintained 18.6% Operating Margin indicate that the core testing-products business remains highly profitable; the revenue fall and the Impairment were concentrated in the lower-margin, more cyclical testing-services activity in China. The rising net cash and the 10% dividend increase reinforce the impression of a fundamentally sound business absorbing a specific, and arguably contained, setback. The question for investors is whether the China weakness is indeed a timing issue, as management contends, or the start of a more persistent challenge in that market.
Catalysts and risks
Identifiable catalysts include the second-half revenue weighting implied by the order book, delivery against full-year consensus, recovery in the China testing-services business, new product and service wins, and the strong net-cash position supporting potential acquisitions and dividends.
The risks include the automotive industry's cyclicality and the specific weakness in China testing services; the concentration of demand among vehicle manufacturers; currency translation given significant overseas revenue; and execution risk on growth initiatives and acquisitions. The exceptional charge highlights that even a high-quality engineer can face market-specific setbacks. As at 14 September 2026 the shares traded at about 834p, capitalising the company at roughly £191 million on London market data — a valuation reflecting its quality and margins, but sensitive to automotive demand and the China recovery.
Avingtrans plc (LSE:AVG)
Avingtrans is a diversified engineering group serving the energy, nuclear, medical and infrastructure markets. Its Advanced Engineering Systems division includes businesses such as Hayward Tyler, which makes pumps and motors for the energy and nuclear sectors, and Booth Industries, which supplies specialist doors and enclosures for infrastructure projects; its Medical and Industrial Imaging division houses developing businesses including Adaptix and Magnetica. Avingtrans is a profitable, cash-generative engineer with exposure to the nuclear revival, energy Investment and, increasingly, medical imaging.
Latest results and divisions
In its interim results for the six months to 30 November 2025, reported in February 2026, Avingtrans held group revenue broadly flat at £78.1 million, but improved profitability markedly: adjusted EBITDA rose 10.4% to £9.6 million and adjusted profit before tax increased 27.1% to £5.7 million, with adjusted Diluted Earnings per Share from continuing operations of 14.6p. Gross margin improved to 31.7%, operating cash inflow strengthened to £7.6 million, and net Debt was stable at £12.3 million excluding Lease obligations; the interim dividend rose around 5% to 2.0p per share.
By division, Advanced Engineering Systems generated £75.2 million of revenue, with Hayward Tyler securing US$16.0 million of new nuclear contracts with KHNP of South Korea and Booth winning £8.5 million of additional HS2 and Transport for London work. The Medical and Industrial Imaging division grew revenue 33% to £2.9 million and narrowed its losses, with Adaptix receiving FDA 510(k) clearance for an orthopaedic system and commencing US sales, and Magnetica expecting a 510(k) submission in the second half. The company reported that its Advanced Engineering Systems order book was secured to achieve more than 95% of full-year market expectations, and highlighted opportunities from AI and data-centre-driven energy demand and next-generation nuclear.
Catalysts and risks
Identifiable catalysts include conversion of the strong order book into full-year results, further nuclear and energy contract wins, commercialisation progress in medical imaging including Adaptix's US sales and Magnetica's regulatory submission, and potential value realisation from its 'buy, improve, sell' strategy.
The risks include the timing and execution of large engineering contracts; exposure to nuclear and energy Capital cycles; the early-stage nature and cash requirements of the medical-imaging ventures; and currency and cost considerations. As at 14 September 2026 the shares traded at about 725p, capitalising the company at roughly £268 million on London market data — a valuation reflecting its profitable core and growth optionality, but dependent on order delivery and the maturation of its imaging businesses.
Gooch & Housego PLC (LSE:GHH)
Gooch & Housego is a photonics group that designs and manufactures optical components and systems for aerospace and defence, industrial and life-sciences markets. Its technologies — including acousto-optics, fibre optics, precision optics and laser components — are used in applications from defence systems and semiconductor Manufacturing to medical devices. It is a profitable, established engineer that has been benefiting from strong demand in aerospace and defence, supported by recent acquisitions, while managing softer conditions in parts of its industrial and life-sciences businesses.
The company's strategy is to grow its higher-value aerospace-and-defence and industrial photonics activities, both organically and through acquisition, while improving margins and converting a growing order book into revenue.
Latest results and record order book
In its interim results for the first half of the 2026 financial year, Gooch & Housego reported revenue up 15.5% to £81.9 million (9.1% on an organic, constant-currency basis), with adjusted profit before tax up 13.9% to £5.8 million and adjusted operating profit up 16.9% to £7.2 million at an improved 8.8% margin. The standout was Aerospace & Defence, where revenue surged 51.7% to £35.6 million (26.0% organic) and adjusted operating profit jumped to £3.6 million from £0.6 million, benefiting from the recent acquisitions of Global Photonics and Phoenix Optical. Industrial revenue was essentially flat at £30.3 million, with recovery visible in semiconductor and laser markets, while Life Sciences revenue declined 7.7% to £16.0 million amid material-supply constraints that compressed its margins.
The company reported a record order book of £167.3 million, up from £142.4 million in September 2025, underlining the strength of demand, particularly in defence. Net debt was £49.8 million including lease obligations (£36.6 million excluding), Leverage was 1.5 times, and the interim dividend was held at 4.9p per share. The board maintained full-year 2026 expectations and expressed confidence in mid-teens returns over the medium term. The combination of booming defence demand and a record order book is the defining feature of the current period.
Catalysts and risks
Identifiable catalysts include conversion of the record order book into revenue, continued strength in aerospace and defence, recovery in the industrial and semiconductor markets, resolution of the life-sciences Supply constraints, integration of recent acquisitions, and margin improvement towards medium-term targets.
The risks include the concentration of recent growth in defence, which carries its own procurement and budget dynamics; the softness and supply issues in life sciences; the debt taken on to fund acquisitions; currency translation; and execution risk on integration and margin improvement. As at 14 September 2026 the shares traded at about 1,205p, capitalising the company at roughly £330 million on London market data — a valuation reflecting the strong order book and defence exposure, but dependent on order conversion and margin delivery.
How the Three FTSE AIM All-Share Stocks Compare
The three companies are all profitable, order-book-driven engineers, but with different end-market exposures. AB Dynamics serves automotive testing and is working through a China setback. Avingtrans spans nuclear, energy and medical imaging with a strong order book. Gooch & Housego is a photonics group riding booming defence demand to a record order book. The table summarises the key metrics; all figures relate to the periods labelled.
|
Company |
LSE Code |
Focus |
Market Cap (approx., 14 Sep 2026) |
Latest Revenue |
Profit Metric |
Cash / Debt |
Key Catalyst |
Key Risk |
|---|---|---|---|---|---|---|---|---|
|
AB Dynamics |
ABDP |
Automotive testing |
~£191m |
£48.8m H1 FY2026 (-16%) |
Adj op profit £9.1m |
Net cash £39.3m |
H2 weighting; China recovery |
Automotive cycle / China |
|
Avingtrans |
AVG |
Nuclear/energy/medical |
~£268m |
£78.1m H1 FY2026 (flat) |
Adj PBT £5.7m (+27%) |
Net debt £12.3m |
Order-book conversion; imaging |
Contract timing / imaging cash |
|
Gooch & Housego |
GHH |
Photonics / defence |
~£330m |
£81.9m H1 FY2026 (+15.5%) |
Adj PBT £5.8m (+14%) |
Net debt £36.6m (ex-leases) |
Record order book conversion |
Defence concentration / debt |
Sources: Marketdata
What Could Drive the Sector Through the Rest of 2026?
Defence and aerospace demand is a powerful tailwind, most visible at Gooch & Housego, where a 52% surge in aerospace-and-defence revenue drove a record order book. Elevated government defence spending, supported by geopolitical tensions, is likely to sustain demand for specialist components and systems, benefiting engineers with relevant exposure and supporting order intake through the rest of 2026.
The nuclear revival and energy investment underpin Avingtrans and parts of the wider sector. New nuclear contracts, such as Hayward Tyler's work with KHNP, and the energy demands of AI and data centres, point to a multi-year opportunity for engineers serving these markets. The pace at which these opportunities convert into orders and revenue will shape performance.
Automotive and industrial cycles cut both ways. AB Dynamics' China setback illustrates how a specific market can disrupt even a structurally growing business, while the recovery visible in semiconductor and laser markets at Gooch & Housego points to improving industrial conditions. The direction of automotive investment — particularly in electrification and autonomy testing — and of industrial capital spending will influence demand.
Order-book conversion, margins and currency form the backdrop. All three companies rely on converting order books into revenue at healthy margins, and the mix of work matters to profitability. Currency movements affect their overseas revenue, and cost trends bear on margins. In a sector of profitable, cash-generative businesses, the market is likely to reward reliable delivery and order-book growth.
Potential Catalysts to Watch
For AB Dynamics, the identifiable catalysts are the second-half revenue weighting and delivery against full-year consensus, recovery in the China testing-services business, new product and service wins, and potential acquisitions supported by its strong net-cash position.
For Avingtrans, watch for full-year results and conversion of the strong order book, further nuclear and energy contract wins, commercialisation progress in medical imaging including Adaptix's US sales and Magnetica's regulatory submission, and any value realisation from its portfolio strategy.
For Gooch & Housego, the key events are conversion of the record order book into revenue, continued aerospace-and-defence strength, recovery in industrial and semiconductor markets, resolution of the life-sciences supply constraints, and margin improvement. As always, these are potential rather than assured outcomes, and their effects could be positive or negative.
Key Risks Investors Should Consider
End-market and concentration risk differs across the three. AB Dynamics is exposed to the automotive cycle and to the specific weakness in China testing services that drove its exceptional charge. Gooch & Housego's recent growth is concentrated in defence, which carries its own procurement and budget dynamics, while its life-sciences business faces supply constraints. Avingtrans depends on the timing of large nuclear and energy contracts.
Execution and balance-sheet considerations apply. Gooch & Housego and Avingtrans carry net debt, partly reflecting acquisitions, and integration and margin-improvement execution is a live task; Avingtrans' medical-imaging ventures are earlier-stage and consume cash. AB Dynamics, though net-cash, must deliver a second-half-weighted year and recover in China. Order-book conversion is not guaranteed and can be affected by delays.
Currency and cyclicality affect all three, given their overseas revenue and exposure to capital-investment cycles. While these are profitable, established engineers rather than speculative junior-market names, they are not risk-free: end-market disruption, contract timing, integration challenges and currency movements can all weigh on results. Readers should weigh these company-specific risks against the sector's supportive structural drivers.
Conclusion
AB Dynamics, Avingtrans and Gooch & Housego represent the quality engineering end of AIM — profitable, cash-generative businesses with order books and exposure to structural growth in automation, nuclear and energy, and defence. AB Dynamics is working through a China testing-services setback while maintaining strong margins and net cash and reaffirming its medium-term growth ambitions. Avingtrans is converting a strong order book across nuclear, energy and infrastructure while nurturing its medical-imaging ventures. Gooch & Housego is riding booming defence demand to a record order book, offset by softer life-sciences conditions.
Defence spending, the nuclear revival, automotive and industrial cycles, and order-book conversion will drive the sector through the rest of 2026. The companies differ in their exposures and near-term challenges — the China setback at AB Dynamics, contract timing at Avingtrans, and defence concentration at Gooch & Housego — but share the quality and cash generation that distinguish them from speculative peers. Market Participants are likely to monitor AB Dynamics' second-half recovery, Avingtrans' order conversion and imaging progress, and Gooch & Housego's order-book delivery. Each carries its own risks, which readers should weigh for themselves. No recommendation to buy, sell or hold is made or implied.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...